Amylyx Pharmaceuticals proposes $350.0M common stock offering
Amylyx Pharmaceuticals (AMLX) announces a proposed $350.0M public offering of common stock, with proceeds to fund avexitide pre-commercial activities, R&D, and general corporate purposes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.